Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

China's Shenzhen gets green light for next wave of reforms

Published 01/25/2022, 11:21 PM
Updated 01/25/2022, 11:30 PM
© Reuters. FILE PHOTO: A giant screen shows news footage of Chinese President Xi Jinping speaking at an event marking the 40th anniversary of the establishment of Shenzhen Special Economic Zone, outside a shopping mall in Beijing, China October 14, 2020.  REUTERS/Ca

SHENZHEN, China (Reuters) - China's state planner has given its blessing for the southern city of Shenzhen to pursue reforms in areas such as relaxed market access for cross border data trading and an electronics trading platform, guidelines published on Wednesday show.

President Xi Jinping has given Shenzhen greater autonomy for pursuing reforms, praising it for "achieving miracles" while on a visit two years ago to mark the establishment of the country's first economic zone in the southern city four decades earlier.

Shenzhen would become a "model city for a strong socialist country," Xi said in October 2020.

The new guidelines from the National Development and Reform Commission (NDRC) further spell out where the city should pursue reforms, across finance, data, medicine, education and elderly care.

The guidelines call on Shenzhen to develop standards for cross-border data transactions, with an eye to transfers between the Greater Bay Area, which includes Hong Kong and Macau.

It also calls on the city to develop trading products related to yuan settlements, and an offshore trading platform, though details are not spelled out.

Shenzhen should also build an international platform for trading electronic components and integrated circuits, providing support on customs declarations and other logistical matters.

In a bid to attract more overseas talent, the city should look into relaxing restrictions on Chinese citizens opening foreign schools, the guidelines said.

Other points including developing a system for online sales of prescription drugs, the relaxation of restrictions on medicines, improving the approval process for stem cell therapy.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.